Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

Alexander L. Gerbes; Joachim Labenz; Beate Appenrodt; Matthias Dollinger; Felix Gundling; Veit Gülberg; Axel Holstege; Petra Lynen-Jansen; Christian J. Steib; Jonel Trebicka; Reiner Wiest; Alexander Zipprich; Collaborators:; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV); Deutsche Gesellschaft für Innere Medizin e. V. (DGIM); Deutsche Gesellschaft für Infektiologie e. V. (DGI); Deutsche Gesellschaft für Pathologie e. V./Bundesverband deutscher Pathologen e. V. (DGP/BDP); Deutsche Röntgengesellschaft e. V. (DRG); Deutsche Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR); Deutsche Gesellschaft für Nephrologie (DGFN); Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Neurologie e. V. (DGN); Deutsche Gesellschaft für Ernährungsmedizin e. V. (DGEM); Lebertransplantierte Deutschland e. V.

doi:10.1055/a-0873-4658

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2019; 57(05): 611-680
DOI: 10.1055/a-0873-4658

Leitlinie

Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

AWMF-Nr.: 021-017Updated S2k-Guideline “Complications of liver cirrhosis”. German Society of Gastroenterology (DGVS)

Alexander L. Gerbes^*

¹Medizinische Klinik und Poliklinik II, Leber Centrum München, Klinikum der Universität München, LMU München

,

Joachim Labenz^*

²Innere Medizin, Diakonie Klinikum Jung-Stilling, Siegen

,

Beate Appenrodt

³Innere Medizin, St. Elisabeth-Krankenhaus, Köln

⁴Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg

,

Matthias Dollinger

⁵Medizinische Klinik I mit Schwerpunkt Gastroenterologie, Klinikum Landshut, Landshut

,

Felix Gundling

⁶Klinik für Gastroenterologie, Hepatologie und gastroent. Onkologie, Klinikum Bogenhausen, München

,

Veit Gülberg

⁷Innere Medizin, Krankenhaus Cham Sana Kliniken, Cham

,

Axel Holstege

⁸Landshut

,

Petra Lynen-Jansen

⁹Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten, Berlin

,

Christian J. Steib

¹⁰Medizinische Klinik und Poliklinik II, Campus Großhadern, Universitätsklinikum München, München

,

Jonel Trebicka

¹¹Medizinische Klinik I Gastroent., Hepat., Pneum., Endokrin., Universitätsklinikum Frankfurt, Frankfurt

,

Reiner Wiest

¹²Bern

,

Alexander Zipprich

¹³Universitätsklinik u. Poliklinik, Innere Medizin I mit Schwerpunkt Gastroenterologie, Universitätsklinikum Halle, Halle

,

Collaborators:

› InstitutsangabenWeitere beteiligte Fachgesellschaften: Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), Deutsche Gesellschaft für Innere Medizin e. V. (DGIM), Deutsche Gesellschaft für Infektiologie e. V. (DGI), Deutsche Gesellschaft für Pathologie e. V./Bundesverband deutscher Pathologen e. V. (DGP/BDP), Deutsche Röntgengesellschaft e. V. (DRG), Deutsche Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR), Deutsche Gesellschaft für Nephrologie (DGFN), Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM), Deutsche Gesellschaft für Neurologie e. V. (DGN), Deutsche Gesellschaft für Ernährungsmedizin e. V. (DGEM) Patientenvertretung: Lebertransplantierte Deutschland e. V.

Abstract

Zusammenfassung

Die Leitlinie Komplikationen der Leberzirrhose der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) ersetzt die Leitlinie aus dem Jahr 2011. Sie basiert auf den Empfehlungen der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) für eine evidenzbasierte Konsensus-Leitlinie der Entwicklungsstufe S2k und wurde interdisziplinär unter Beteiligung aller relevanten Fachgesellschaften und der Patientenvertretung erstellt. Neben den in der Vorgängerversion behandelten Kapiteln Aszites, spontan bakterielle Peritonitis, hepatorenales Syndrom, hepatischer Hydrothorax und hepatopulmonales Syndrom wurden die Kapitel Diagnostik und Therapie der Hepatischen Enzephalopathie neu aufgenommen.

Abstract

This guideline provides evidence-based key recommendations for diagnosis and therapy of complications of liver cirrhosis and upgrades the 2011 version. An interdisciplinary team of medical experts and patient support groups developed the guideline following the AWMF recommendations for evidence based consensus guidelines. New chapters concerning diagnosis and therapy of hepatic encephalopathy were added.

Volltext

Referenzen

Literatur
1 Runyon BA, Committee APG. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107
2 Arroyo V, Fernandez-Esparrach G, Gines P. Diagnostic approach to the cirrhotic patient with ascites. J Hepatol 1996; 25: 35-40
3 Cardenas A, Chopra S. Chylous ascites. Am J Gastroenterol 2002; 97: 1896-1900
4 Almakdisi T, Massoud S, Makdisi G. Lymphomas and chylous ascites: review of the literature. Oncologist 2005; 10: 632-635
5 Kim JJ, Tsukamoto MM, Mathur AK. et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol 2014; 109: 1436-1442
6 Runyon BA. Early events in spontaneous bacterial peritonitis. Gut 2004; 53: 782-784
7 Castellote J, Girbau A, Maisterra S. et al. Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic outpatients undergoing large-volume paracentesis. J Gastroenterol Hepatol 2008; 23: 256-259
8 Jeffries MA, Stern MA, Gunaratnam NT. et al. Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis. Am J Gastroenterol 1999; 94: 2972-2976
9 Evans LT, Kim WR, Poterucha JJ. et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37: 897-901
10 Angeloni S, Nicolini G, Merli M. et al. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003; 98: 1844-1848
11 Böcking A, Motherby H, Pomjanski N. Treffsicherheit der Ergusszytologie samt adjuvanten Untersuchungsmethoden. Dtsch Arztebl International 2000; 97: 2626-2630
12 Motherby H, Nadjari B, Friegel P. et al. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999; 20: 350-357
13 Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 (Suppl. 06) vi1-v12
14 Schlake W, Kreipe H. Mitteilungen Deutsche Gesellschaft für Pathologie. Erklärung zur Zytopathologie. Unter Mitarbeit von: A. Böcking, R. Bollmann, S. Falk, V. Fritzsche, A. Wellmann. Der Pathologe 2007; 28: 393
15 Spriggs AI, Boddington MM. The Cytology of Effusions: Pleural, Pericardial and Peritoneal and of Cerebrospinal Fluid. Elsevier Science; 2016
16 Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4: 721-723
17 Zakeri N, Tsochatzis EA. Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep 2017; 19: 45
18 Grabau CM, Crago SF, Hoff LK. et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 484-488
19 McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 164-71
20 Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986; 146: 2259-2261
21 Kurup AN, Lekah A, Reardon ST. et al. Bleeding Rate for Ultrasound-Guided Paracentesis in Thrombocytopenic Patients. J Ultrasound Med 2015; 34: 1833-1838
22 Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: mit 19 Tabellen. Dt. Ärzte-Verlag; 2009
23 Wolfe KS, Kress JP. Risk of Procedural Hemorrhage. Chest 2016; 150: 237-246
24 Runyon BA. Aasld. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651-1653
25 Dietrich CF, Lorentzen T, Appelbaum L. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Short Version). Ultraschall in Med 2016; 37: 27-45
26 Lentschener C, Flaujac C, Ibrahim F. et al. Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study. Eur J Anaesthesiol 2016; 33: 126-133
27 Strobel D, Bernatik T, Blank W. et al. Incidence of bleeding in 8172 percutaneous ultrasound- guided intraabdominal diagnostic and therapeutic interventions – results of the prospective multicenter DEGUM interventional ultrasound study (PIUS study). Ultraschall in Med 2015; 36: 122-131
28 Devarbhavi H, Murali AR. Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio. J Clin Exp Hepatol 2015; 5: 310-313
29 Atwell TD, Smith RL, Hesley GK. et al. Incidence of bleeding after 15 181 percutaneous biopsies and the role of aspirin. Am J Roentgenol 2010; 194: 784-789
30 Patel IJ, Davidson JC, Nikolic B. et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012; 23: 727-736
31 Patel IJ, Davidson JC, Nikolic B. et al. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol 2013; 24: 641-645
32 Denzer U, Beilenhoff U, Eickhoff A. et al. S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021–022. Z Gastroenterol 2015; 53: E1-E227
33 Acosta RD, Abraham NS. Committee ASoP. et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83: 3-16
34 KRINKO. Anforderungen der Hygiene bei Operationen und anderen invasiven Eingriffen. Robert Koch-Institut; 2000
35 Schlottmann K, Gelbmann C, Grune S. et al. A new paracentesis needle for ascites and pleural effusion compared with the venous indwelling catheter. A prospective, randomized study. Med Klin (Munich) 2001; 96: 321-324
36 Gines P, Arroyo V, Rodes J. Treatment of ascites and renal failure in cirrhosis. Baillieres Clin Gastroenterol 1989; 3: 165-186
37 Shaheen NJ, Grimm IS. Comparison of the Caldwell needle/cannula with Angiocath needle in large volume paracentesis. Am J Gastroenterol 1996; 91: 1731-1733
38 Boccia S, Rollo V, Accorsi L. et al. Paracentesis: a new needle for an old technique. Endoscopy 1991; 23: 83-84
39 Nazeer SR, Dewbre H, Miller AH. Ultrasound-assisted paracentesis performed by emergency physicians vs the traditional technique: a prospective, randomized study. Am J Emerg Med 2005; 23: 363-367
40 Sakai H, Sheer TA, Mendler MH. et al. Choosing the location for non-image guided abdominal paracentesis. Liver Int 2005; 25: 984-986
41 Cattau Jr EL, Benjamin SB, Knuff TE. et al. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982; 247: 1164-1166
42 Irshad A, Ackerman SJ, Anis M. et al. Can the smallest depth of ascitic fluid on sonograms predict the amount of drainable fluid?. J Clin Ultrasound 2009; 37: 440-444
43 Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest 2013; 143: 532-538
44 De Gottardi A, Thevenot T, Spahr L. et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7: 906-909
45 Martinet O, Reis ED, Mosimann F. Delayed hemoperitoneum following large-volume paracentesis in a patient with cirrhosis and ascites. Dig Dis Sci 2000; 45: 357-358
46 Arnold C, Haag K, Blum HE. et al. Acute hemoperitoneum after large-volume paracentesis. Gastroenterology 1997; 113: 978-982
47 Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21: 525-529
48 Mallory A, Schaefer JW. Complications of diagnostic paracentesis in patients with liver disease. JAMA 1978; 239: 628-630
49 Lin CH, Shih FY, Ma MH. et al. Should bleeding tendency deter abdominal paracentesis?. Dig Liver Dis 2005; 37: 946-951
50 Webster ST, Brown KL, Lucey MR. et al. Hemorrhagic complications of large volume abdominal paracentesis. Am J Gastroenterol 1996; 91: 366-368
51 Minocha A. A fatal case of paracentesis. Am J Gastroenterol 1999; 94: 856
52 Sharzehi K, Jain V, Naveed A. et al. Hemorrhagic complications of paracentesis: a systematic review of the literature. Gastroenterol Res Pract 2014; 2014: 985141
53 Campillo B, Richardet JP, Dupeyron C. Diagnostic value of two reagent strips (Multistix 8 SG and Combur 2 LN) in cirrhotic patients with spontaneous bacterial peritonitis and symptomatic bacterascites. Gastroenterol Clin Biol 2006; 30: 446-452
54 Rimola A, Garcia-Tsao G, Navasa M. et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. Journal of hepatology 2000; 32: 142-153
55 Albillos A, Cuervas-Mons V, Millan I. et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology 1990; 98: 134-140
56 Jones SR. The absolute granulocyte count in ascites fluid. An aid to the diagnosis of spontaneous bacterial peritonitis. West J Med 1977; 126: 344-346
57 Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343-1346
58 Llach J, Rimola A, Navasa M. et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724-727
59 Guarner C, Sola R, Soriano G. et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999; 117: 414-419
60 Canete N, Erice E, Bargallo A. et al. Natural History of Spontaneous Bacterial Peritonitis: A Longitudinal Study in 263 Cirrhotic Patients After the First Ascites Decompensation. Journal of Hepatology 2007; 46: S90-S91
61 Pare P, Talbot J, Hoefs JC. Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology 1983; 85: 240-244
62 Runyon BA, Montano AA, Akriviadis EA. et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215-220
63 Dittrich S, Yordi LM, de Mattos AA. The value of serum-ascites albumin gradient for the determination of portal hypertension in the diagnosis of ascites. Hepato-gastroenterology 2001; 48: 166-168
64 Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95: 1351-1355
65 Castellote J, Xiol X, Verdaguer R. et al. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990; 85: 1605-1608
66 Bobadilla M, Sifuentes J, Garcia-Tsao G. Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1989; 27: 2145-2147
67 Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358
68 Kuiper JJ, van Buuren HR, de Man RA. Limited role for routine ascitic culture as a diagnostic tool for spontaneous bacterial peritonitis in the era of prophylactic antibiotics. Journal of Hepatology 2007; 46: S96
69 Butani RC, Shaffer RT, Szyjkowski RD. et al. Rapid diagnosis of infected ascitic fluid using leukocyte esterase dipstick testing. Am J Gastroenterol 2004; 99: 532-537
70 Castellote J, Lopez C, Gornals J. et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 2003; 37: 893-896
71 Sapey T, Kabissa D, Fort E. et al. Instant diagnosis of spontaneous bacterial peritonitis using leukocyte esterase reagent strips: Nephur-Test vs. MultistixSG. Liver Int 2005; 25: 343-348
72 Thevenot T, Cadranel JF, Nguyen-Khac E. et al. Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients by use of two reagent strips. Eur J Gastroenterol Hepatol 2004; 16: 579-583
73 Vanbiervliet G, Rakotoarisoa C, Filippi J. et al. Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2002; 14: 1257-1260
74 Nousbaum JB, Cadranel JF, Nahon P. et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007; 45: 1275-1281
75 Gulberg V, Gerbes AL, Sauerbruch T. et al. Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis. Hepatology 2007; 46: 1669 ; author reply 1669–1670
76 Nguyen-Khac E, Cadranel JF, Thevenot T. et al. Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther 2008; 28: 282-288
77 Such J, Frances R, Munoz C. et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-141
78 Bruns T, Sachse S, Straube E. et al. Identification of bacterial DNA in neutrocytic and non- neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009; 29: 1206-1214
79 Appenrodt B, Lehmann LE, Thyssen L. et al. Is detection of bacterial DNA in ascitic fluid of clinical relevance?. Eur J Gastroenterol Hepatol 2010; 22: 1487-1494
80 Bruns T, Reuken PA, Stengel S. et al. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int 2016; 36: 1133-1142
81 Gerbes AL, Jungst D, Xie YN. et al. Ascitic fluid analysis for the differentiation of malignancy- related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer 1991; 68: 1808-1814
82 Jungst D, Gerbes AL, Martin R. et al. Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology 1986; 6: 239-243
83 Jungst D, Xie Y, Gerbes AL. Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. J Hepatol 1992; 14: 244-248
84 Du L, Zhu S, Lu Z. et al. Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal-hypertensive ascites and the diagnosis of mixed ascites. Alimentary Pharm Ther [Epub 2018]
85 Gulyas M, Kaposi AD, Elek G. et al. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol 2001; 54: 831-835
86 Gerbes AL, Xie YN, Mezger J. et al. Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. Liver 1990; 10: 152-157
87 Soriano G, Castellote J, Alvarez C. et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010; 52: 39-44
88 Caralis PV, Sprung CL, Schiff ER. Secondary bacterial peritonitis in cirrhotic patients with ascites. South Med J 1984; 77: 579-583
89 Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 1984; 4: 447-450
90 Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990; 98: 127-133
91 Garrison RN, Cryer HM, Howard DA. et al. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984; 199: 648-655
92 Wu SS, Lin OS, Chen YY. et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol 2001; 34: 215-221
93 Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 111-123
94 Le S, Spelman T, Chong CP. et al. Could Adherence to Quality of Care Indicators for Hospitalized Patients With Cirrhosis-Related Ascites Improve Clinical Outcomes?. Am J Gastroenterol 2016; 111: 87-92
95 D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231
96 Guardiola J, Baliellas C, Xiol X. et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002; 97: 2374-2378
97 Planas R, Montoliu S, Balleste B. et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-1394
98 Gines P, Cardenas A, Arroyo V. et al. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
99 Peng S, Plank LD, McCall JL. et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr 2007; 85: 1257-1266
100 Amodio P, Bemeur C, Butterworth R. et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325-336
101 Montano-Loza AJ, Meza-Junco J, Prado CM. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166-173, 173 e1
102 Durand F, Buyse S, Francoz C. et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60: 1151-1157
103 Carey EJ, Lai JC, Wang CW. et al. A multicenter study to define sarcopenia in patients with end- stage liver disease. Liver Transpl 2017; 23: 625-633
104 Borhofen SM, Gerner C, Lehmann J. et al. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. Dig Dis Sci 2016; 61: 1735-1743
105 Montano-Loza AJ, Angulo P, Meza-Junco J. et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016; 7: 126-135
106 Selberg O, Selberg D. Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur J Appl Physiol 2002; 86: 509-516
107 Peres WA, Lento DF, Baluz K. et al. Phase angle as a nutritional evaluation tool in all stages of chronic liver disease. Nutr Hosp 2012; 27: 2072-2078
108 Ruiz-Margain A, Macias-Rodriguez RU, Duarte-Rojo A. et al. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. Dig Liver Dis 2015; 47: 309-314
109 Belarmino G, Gonzalez MC, Torrinhas RS. et al. Phase angle obtained by bioelectrical impedance analysis independently predicts mortality in patients with cirrhosis. World J Hepatol 2017; 9: 401-408
110 Figueiredo FA, Dickson ER, Pasha TM. et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl 2000; 6: 575-581
111 Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005; 21: 113-117
112 Huisman EJ, Trip EJ, Siersema PD. et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011; 23: 982-989
113 Norman K, Kirchner H, Freudenreich M. et al. Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease--a randomized controlled trial. Clin Nutr 2008; 27: 48-56
114 Plauth M, Cabre E, Campillo B. et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr 2009; 28: 436-444
115 Plank LD, Gane EJ, Peng S. et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology 2008; 48: 557-566
116 Plauth M, Schutz T, Buckendahl DP. et al. Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. J Hepatol 2004; 40: 228-233
117 Cordoba J, Lopez-Hellin J, Planas M. et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43
118 Everhart JE, Lok AS, Kim HY. et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-557
119 Berzigotti A, Garcia-Tsao G, Bosch J. et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54: 555-561
120 Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999; 13: 126-130
121 Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-109
122 Dick AA, Spitzer AL, Seifert CF. et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009; 15: 968-977
123 Berzigotti A, Albillos A, Villanueva C. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology 2017; 65: 1293-1305
124 Madden AM, Bradbury W, Morgan MY. Taste perception in cirrhosis: its relationship to circulating micronutrients and food preferences. Hepatology 1997; 26: 40-48
125 Bernardi M, Laffi G, Salvagnini M. et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156-162
126 Gu XB, Yang XJ, Zhu HY. et al. Effect of a diet with unrestricted sodium on ascites in patients with hepatic cirrhosis. Gut Liver 2012; 6: 355-361
127 Sorrentino P, Castaldo G, Tarantino L. et al. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. J Gastroenterol Hepatol 2012; 27: 813-822
128 Angeli P, Wong F, Watson H. et al. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-1542
129 Biggins SW, Kim WR, Terrault NA. et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660
130 Kim WR, Biggins SW, Kremers WK. et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-1026
131 Abbasoglu O, Goldstein RM, Vodapally MS. et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998; 12: 263-269
132 Perez-Ayuso RM, Arroyo V, Planas R. et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84: 961-968
133 Santos J, Planas R, Pardo A. et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003; 39: 187-192
134 Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90: 1827-1833
135 Gatta A, Angeli P, Caregaro L. et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14: 23123-23126
136 Daskalopoulos G, Laffi G, Morgan T. et al. Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. Gastroenterology 1987; 92: 1859-1863
137 Licata G, Tuttolomondo A, Licata A. et al. Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther 2009; 30: 227-235
138 Yakar T, Demir M, Dogan O. et al. High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. Clin Invest Med 2016; 39: 27502
139 Abecasis R, Guevara M, Miguez C. et al. Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. Scand J Gastroenterol 2001; 36: 309-313
140 Gerbes AL, Bertheau-Reitha U, Falkner C. et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J Hepatol 1993; 17: 353-358
141 Angeli P, Fasolato S, Mazza E. et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59: 98-104
142 Stanley MM, Ochi S, Lee KK. et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989; 321: 1632-1638
143 Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342
144 Yang YY, Lin HC, Lee WP. et al. Association of the G-protein and alpha2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. Gut 2010; 59: 1545-1553
145 Singh V, Singh A, Singh B. et al. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Am J Gastroenterol 2013; 108: 560-567
146 Singh V, Dhungana SP, Singh B. et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354
147 Angeli P, Dalla Pria M, De Bei E. et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994; 19: 72-79
148 Pizarro M, Solis N, Quintero P. et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int 2015; 35: 2129-2138
149 Gerbes AL, Gulberg V, Sauerbruch T. et al. German S 3-guideline “ascites, spontaneous bacterial peritonitis, hepatorenal syndrome”. Z Gastroenterol 2011; 49: 749-779
150 Gines P, Wong F, Watson H. et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204-213
151 Wong F, Gines P, Watson H. et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010; 53: 283-290
152 Gines P, Wong F, Watson H. et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010; 31: 834-845
153 Wong F, Watson H, Gerbes A. et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61: 108-116
154 Cardenas A, Gines P, Marotta P. et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012; 56: 571-578
155 Sakaida I, Yanase M, Kobayashi Y. et al. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res 2012; 40: 2381-2393
156 Sakaida I, Yamashita S, Kobayashi T. et al. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res 2013; 41: 835-847
157 Sakaida I, Kawazoe S, Kajimura K. et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73-82
158 Okita K, Kawazoe S, Hasebe C. et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 83-91
159 Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77: 215-222
160 Planas R, Arroyo V, Rimola A. et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983; 84: 247-252
161 Pariente EA, Bataille C, Bercoff E. et al. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985; 88: 1255-1259
162 Daskalopoulos G, Pinzani M, Murray N. et al. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987; 4: 330-336
163 Laffi G, La Villa G, Pinzani M. et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 530-548
164 Gentilini P, Romanelli RG, La Villa G. et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104: 588-94
165 Lee JK, Hsieh JF, Tsai SC. et al. Effects of single dose of 50mg captopril in patients with liver cirrhosis and ascites. Hepatogastroenterology 2000; 47: 767-770
166 Claria J, Kent JD, Lopez-Parra M. et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579-587
167 Zapater P, Llanos L, Barquero C. et al. Acute effects of dipyrone on renal function in patients with cirrhosis: a randomized controlled trial. Basic Clin Pharmacol Toxicol 2015; 116: 257-263
168 Mandorfer M, Bota S, Schwabl P. et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-1690 e1
169 Serste T, Melot C, Francoz C. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-1022
170 Leithead JA, Rajoriya N, Tehami N. et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015; 64: 1111-1119
171 Mookerjee RP, Pavesi M, Thomsen KL. et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. Journal of Hepatology 2016; 64: 574-582
172 Angeli P, Gines P, Wong F. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015; 64: 531-537
173 de Franchis R, Faculty BV. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of Hepatology 2015; 63: 743-752
174 Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother 2015; 49: 207-219
175 Choi EJ, Lee HJ, Kim KO. et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011; 46: 616-620
176 Min YW, Lim KS, Min BH. et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther 2014; 40: 695-704
177 Dam G, Vilstrup H, Watson H. et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016; 64: 1265-1272
178 Mandorfer M, Bota S, Schwabl P. et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One 2014; 9: e110503
179 Terg R, Casciato P, Garbe C. et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol 2015; 62: 1056-1060
180 Caraceni P, Riggio O, Angeli P. et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391: 2417-2429
181 Di Pascoli M, Fasolato S, Piano S. et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int [Epub 2018]
182 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
183 Arroyo V, Gines P, Gerbes AL. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
184 Bellot P, Welker MW, Soriano G. et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013; 58: 922-927
185 Thomas MN, Sauter GH, Gerbes AL. et al. Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg 2015; 400: 979-983
186 Bureau C, Adebayo D, Chalret de Rieu M. et al. Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol 2017; 67: 940-949
187 Sola E, Sanchez-Cabus S, Rodriguez E. et al. Effects of alfapump system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transpl 2017; 23: 583-593
188 Solbach P, Honer Zu Siederdissen C, Taubert R. et al. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. Eur J Gastroenterol Hepatol 2017; 29: 539-546
189 Rosemurgy AS, Zervos EE, Clark WC. et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004; 239: 883-889 ; discussion 889–891
190 Nicolaou S, Talsky A, Khashoggi K. et al. Ultrasound-guided interventional radiology in critical care. Crit Care Med 2007; 35: S186-S197
191 Gines A, Fernandez-Esparrach G, Monescillo A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-1010
192 Gines P, Tito L, Arroyo V. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-1502
193 Pozzi M, Osculati G, Boari G. et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 709-719
194 Tan HK, James PD, Wong F. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Dig Dis Sci 2016; 61: 3084-3092
195 Lebrec D, Giuily N, Hadengue A. et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25: 135-144
196 Wong F, Sniderman K, Liu P. et al. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122: 816-822
197 Brensing KA, Textor J, Perz J. et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295
198 Tan HK, James PD, Sniderman KW. et al. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol 2015; 30: 389-395
199 Allegretti AS, Ortiz G, Cui J. et al. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016; 68: 381-391
200 Gines P, Uriz J, Calahorra B. et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847
201 Rossle M, Ochs A, Gulberg V. et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-1707
202 Salerno F, Camma C, Enea M. et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-834
203 Bureau C, Thabut D, Oberti F. et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology 2017; 152: 157-163
204 Gulberg V, Liss I, Bilzer M. et al. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002; 66: 127-130
205 Salerno F, Merli M, Riggio O. et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-635
206 Bai M, Qi XS, Yang ZP. et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20: 2704-2714
207 Bureau C, Garcia Pagan JC, Layrargues GP. et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27: 742-747
208 Bureau C, Garcia-Pagan JC, Otal P. et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-475
209 Hernandez-Guerra M, Turnes J, Rubinstein P. et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40: 1197-1202
210 Perarnau JM, Baju A, D’Alteroche L. et al. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol 2010; 22: 1093-1098
211 Barrio J, Ripoll C, Banares R. et al. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. Eur J Radiol 2005; 55: 120-124
212 Yang Z, Han G, Wu Q. et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta- analysis. J Gastroenterol Hepatol 2010; 25: 1718-1725
213 Nardelli S, Lattanzi B, Torrisi S. et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol 2017; 15: 934-936
214 Wang Q, Lv Y, Bai M. et al. Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol 2017; 67: 508-516
215 Sauerbruch T, Mengel M, Dollinger M. et al. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology 2015; 149: 660-668 e1
216 Holster IL, Tjwa ET, Moelker A. et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology 2016; 63: 581-589
217 Chalasani N, Clark WS, Martin LG. et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000; 118: 138-144
218 Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis. J Vasc Interv Radiol 2002; 13: 155-161
219 Gerbes AL, Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology 2005; 41: 217
220 Bureau C, Metivier S, D’Amico M. et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol 2011; 54: 901-907
221 Cazzaniga M, Salerno F, Pagnozzi G. et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56: 869-875
222 Lv Y, He C, Wang Z. et al. Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. Radiology 2017; 285: 999-1010
223 Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990; 12: 710-715
224 Fernández J, Navasa M, Gómez J. et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-148
225 Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: variations on a theme. Medicine (Baltimore) 1971; 50: 161-197
226 Gines P, Rimola A, Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716-724
227 Titó L, Rimola A, Gines P. et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31
228 Hsieh WJ, Lin HC, Hwang SJ. et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998; 93: 962-966
229 Pauwels A, Mostefa-Kara N, Debenes B. et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996; 24: 802-806
230 Rolachon A, Cordier L, Bacq Y. et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22: 1171-1174
231 Soriano G, GUARNER C, Teixidó M. et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-481
232 Obstein KL, Campbell MS, Reddy KR. et al. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. The American Journal of Gastroenterology 2007; 102: 2732-2736
233 Bajaj JS, Zadvornova Y, Heuman DM. et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-1134
234 Appenrodt B, Grünhage F, Gentemann MG. et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-1333
235 Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Digestive Diseases and Sciences 1995; 40: 561-565
236 Follo A, Llovet JM, Navasa M. et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501
237 Nobre SR, Cabral JEP, Gomes JJF. et al. In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. European journal of gastroenterology & hepatology 2008; 20: 1176-1181
238 Pinzello G, Simonetti RG, Craxì A. et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983; 3: 545-549
239 Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. The American Journal of Gastroenterology 2001; 96: 1232-1236
240 Toledo C, Salmeron JM, Rimola A. et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251-257
241 Andreu M, Sola R, Sitges-Serra A. et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 1133-1138
242 Silvain C, Besson I, Ingrand P. et al. Prognosis and long-term recurrence of spontaneous bacterial peritonitis in cirrhosis. Journal of Hepatology 1993; 19: 188-189
243 Terg R, Levi D, Lopez P. et al. Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease. Dig Dis Sci 1992; 37: 1499-504
244 Altman C, Grangé JD, Amiot X. et al. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. Journal of Gastroenterology and Hepatology 1995; 10: 47-50
245 Almdal TP, Skinhøj P. Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis. Scandinavian Journal of Gastroenterology 1987; 22: 295-300
246 Weinstein MP, Iannini PB, Stratton CW. et al. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978; 64: 592-598
247 Terg R, Gadano A, Cartier M. et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver international: official journal of the International Association for the Study of the Liver 2009; 29: 415-419
248 França AV, De Souza JB, Silva CM. et al. Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with ceftriaxone. Journal of clinical gastroenterology 2001; 33: 295-298
249 Kamani L, Mumtaz K, Ahmed US. et al. Outcomes in culture positive and culture negative ascitic fluid infection in patients with viral cirrhosis: cohort study. BMC Gastroenterology 2008; 8: 59
250 Cho JH, Park KH, Kim SH. et al. Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis. Scandinavian journal of infectious diseases 2007; 39: 697-702
251 Gotz M, Anders M, Biecker E. et al. S2k Guideline Gastrointestinal Bleeding – Guideline of the German Society of Gastroenterology DGVS. Z Gastroenterol 2017; 55: 883-936
252 DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther 2016; 43 (Suppl. 01) 3-10
253 DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram- negative flora and enterococci. Clin Microbiol Infect 2004; 10: 1009-1011
254 Tandon P, Delisle A, Topal JE. et al. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol 2012; 10: 1291-1298
255 De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979-981
256 Assem M, Elsabaawy M, Abdelrashed M. et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int 2016; 10: 377-385
257 Fernández J, Navasa M, Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824
258 Hanouneh MA, Hanouneh IA, Hashash JG. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46: 709-715
259 Vlachogiannakos J, Viazis N, Vasianopoulou P. et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-455
260 Lontos S, Gow PJ, Vaughan RB. et al. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2008; 23: 252-255
261 Singh N, Gayowski T, Yu VL. et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122: 595-598
262 Lontos S, Shelton E, Angus PW. et al. A randomized controlled study of trimethoprim- sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014; 15: 260-267
263 Jalan R, Fernández J, Wiest R. et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. Journal of hepatology 2014; 60: 1310-1324
264 Gustot T, Fernández J, Szabo G. et al. Sepsis in Alcohol-related Liver Disease. Journal of Hepatology 2017; 67: 1031-1050
265 Navasa M, Follo A, Llovet JM. et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111: 1011-1017
266 Park YH, Lee HC, Song HG. et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. Journal of Gastroenterology and Hepatology 2003; 18: 927-933
267 Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003; 9: 531-537
268 Lutz P, Nischalke HD, Krämer B. et al. Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis. European journal of clinical investigation 2016; 47: 44-52
269 Friedrich K, Nüssle S, Rehlen T. et al. Microbiology and resistance in first episodes of spontaneous bacterial peritonitis: implications for management and prognosis. Journal of Gastroenterology and Hepatology 2016; 31: 1191-1195
270 Reuken PA, Pletz MW, Baier M. et al. Emergence of spontaneous bacterial peritonitis due to enterococci – risk factors and outcome in a 12-year retrospective study. Alimentary Pharmacology & Therapeutics 2012; 35: 1199-1208
271 Venditti M, Falcone M, Corrao S. et al. Outcomes of patients hospitalized with community- acquired, health care-associated, and hospital-acquired pneumonia. Annals of Internal Medicine 2009; 150: 19-26
272 Merli M, Lucidi C. Bacterial resistance in cirrhotic patients: an emerging reality. Journal of Hepatology 2012; 56: 756-757
273 Friedman ND, Kaye KS, Stout JE. et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of Internal Medicine 2002; 137: 791-797
274 Ariza X, Castellote J, Lora-Tamayo J. et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. Journal of Hepatology 2012; 56: 825-832
275 Rimola A, Navasa M, Arroyo V. Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Diagnostic microbiology and infectious disease 1995; 22: 141-145
276 Rimola A, Salmeron JM, Clemente G. et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21: 674-679
277 Gómez-Jiménez J, Ribera E, Gasser I. et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrobial agents and chemotherapy 1993; 37: 1587-1592
278 Felisart J, Rimola A, Arroyo V. et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457-462
279 Angeloni S, Leboffe C, Parente A. et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World Journal of Gastroenterology 2008; 14: 2757-2762
280 Yakar T, Güçlü M, Serin E. et al. A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Digestive Diseases and Sciences 2010; 55: 1149-1154
281 Piano S, Fasolato S, Salinas F. et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology 2016; 63: 1299-1309
282 Jindal A, Kumar M, Bhadoria AS. et al. A randomized open label study of ‘imipenem vs. cefepime’ in spontaneous bacterial peritonitis. Liver Int 2016; 36: 677-687
283 Umgelter A, Reindl W, Miedaner M. et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37: 2-8
284 Dupeyron C, Campillo SB, Mangeney N. et al. Carriage of Staphylococcus aureus and of gram- negative bacilli resistant to third-generation cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections. Infection control and hospital epidemiology 2001; 22: 427-432
285 Dupeyron C, Mangeney N, Sedrati L. et al. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrobial agents and chemotherapy 1994; 38: 340-344
286 Chavez-Tapia NC, Soares-Weiser K, Brezis M. et al. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. The Cochrane database of systematic reviews 2009; 23: CD002232
287 Chen TA, Lo GH, Lai KH. et al. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World Journal of Gastroenterology 2005; 11: 6823-6827
288 Rastegar LA, Umrani G, Dehbashi N. et al. Evaluation of the therapeutic effect of pefloxacin in comparison with ampicillin and gentamicin in cirrhotic patients with spontaneous bacterial peritonitis. Hepato-gastroenterology 1998; 45: 783-785
289 Antillon MR, Runyon BA. Effect of marked peripheral leukocytosis on the leukocyte count in ascites. Archives of internal medicine 1991; 151: 509-510
290 Ljubicic N, Spajic D, Vrkljan MM. et al. The value of ascitic fluid polymorphonuclear cell count determination during therapy of spontaneous bacterial peritonitis in patients with liver cirrhosis. Hepato-gastroenterology 2000; 47: 1360-1363
291 Runyon BA, Hoefs JC. Spontaneous vs secondary bacterial peritonitis. Differentiation by response of ascitic fluid neutrophil count to antimicrobial therapy. Archives of internal medicine 1986; 146: 1563-1565
292 Fong TL, Akriviadis EA, Runyon BA. et al. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989; 9: 423-426
293 Runyon BA, McHutchison JG, Antillon MR. et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100: 1737-1742
294 Sort P, Navasa M, Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New England Journal of Medicine 1999; 341: 403-409
295 Fernández J, Monteagudo J, Bargallo X. et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-634
296 de Araujo A, de Barros Lopes A, Rossi G. et al. Low-dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?. Gut 2012; 61: 1371-1372
297 Sigal SH, Stanca CM, Fernandez J. et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597-599
298 Salerno F, Navickis RJ, Wilkes MM. Albumin Infusion Improves Outcomes of Patients With Spontaneous Bacterial Peritonitis: A Meta-analysis of Randomized Trials. Clinical Gastroenterology and Hepatology 2013; 11: 123-130.e1
299 Bauer TM, Follo A, Navasa M. et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002; 47: 1356-1361
300 Elfert A, Abo Ali L, Soliman S. et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016; 28: 1450-1454
301 Mostafa T, Badra G, Abdallah M. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. Turk J Gastroenterol 2015; 26: 163-169
302 Alvarez RF, Mattos AA, Correa EB. et al. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol 2005; 42: 256-262
303 Shamseya MM, Madkour MA. Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis. Alexandria Journal of Medicine 2016; 52: 219-226
304 Soriano G, Guarner C, Teixido M. et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-481
305 Sidhu GS, Go A, Attar BM. et al. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol 2017; 4: e000154
306 Kamal F, Khan MA, Khan Z. et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017; 29: 1109-1117
307 Salerno F, Gerbes A, Gines P. et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
308 Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 1135-1140
309 Wong F, Nadim MK, Kellum JA. et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709
310 Moreau R, Jalan R, Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437, 1437 e1–9
311 Jalan R, Saliba F, Pavesi M. et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-1047
312 Barosa R, Roque Ramos L, Patita M. et al. CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward. Rev Esp Enferm Dig 2017; 109: 399-405
313 Li N, Huang C, Yu KK. et al. Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure: The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF. Medicine (Baltimore) 2017; 96: e6802
314 Gerbes AL, Gulberg V, Bilzer M. et al. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-110
315 Markwardt D, Holdt L, Steib C. et al. Plasma cystatin C is a predictor of renal dysfunction, acute- on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology 2017; 66: 1232-1241
316 Maiwall R, Kumar A, Bhardwaj A. et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study. Liver Int 2018; 38: 654-664
317 Seo YS, Park SY, Kim MY. et al. Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. J Gastroenterol Hepatol 2018; 33: 910-917
318 Solanki P, Chawla A, Garg R. et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156
319 Sanyal AJ, Boyer T, Garcia-Tsao G. et al. A randomized, prospective, double-blind, placebo- controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368
320 Martin-Llahi M, Pepin MN, Guevara M. et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359
321 Neri S, Pulvirenti D, Malaguarnera M. et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830-835
322 Ortega R, Gines P, Uriz J. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948
323 Saner F, Kavuk I, Lang H. et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 2004; 9: 78-82
324 Dart AB, Mutter TC, Ruth CA. et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; 20: CD007594
325 Fabrizi F, Dixit V, Messa P. et al. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs 2009; 32: 133-140
326 Gluud LL, Christensen K, Christensen E. et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584
327 Sagi SV, Mittal S, Kasturi KS. et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25: 880-885
328 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i. v. bolus administration. Gastroenterology 2009; 137: 1179 ; author reply 1179–1181
329 Cavallin M, Piano S, Romano A. et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 2016; 63: 983-992
330 Nassar Junior AP, Farias AQ, LA DA. et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014; 9: e107466
331 Gerbes AL, Gulberg V, Waggershauser T. et al. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28: 683-688
332 Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59: 988-1000
333 Guevara M, Gines P, Bandi JC. et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422
334 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64
335 Testino G, Ferro C, Sumberaz A. et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50: 1753-1755
336 Witzke O, Baumann M, Patschan D. et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. J Gastroenterol Hepatol 2004; 19: 1369-1373
337 Mitzner SR, Stange J, Klammt S. et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
338 Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010; 59: 381-386
339 Banares R, Nevens F, Larsen FS. et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57: 1153-1162
340 Rifai K, Ernst T, Kretschmer U. et al. Prometheus--a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-990
341 Kribben A, Gerken G, Haag S. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-789 e3
342 Gonwa TA, Poplawski S, Paulsen W. et al. Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant. Transplantation 1989; 47: 395-397
343 Seu P, Wilkinson AH, Shaked A. et al. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991; 57: 806-809
344 Lafayette RA, Pare G, Schmid CH. et al. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159-164
345 Restuccia T, Ortega R, Guevara M. et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-146
346 Bundesärztekammer. Richtlinien zur Organtransplantation gem. § 16 Abs. 1 S. 1 Nrn. 2, 4u. 5 TPG. Dtsch Arztebl International 2010; 107: 1532-1541
347 Davis CL, Feng S, Sung R. et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: 1702-1709
348 Galie N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
349 Lieberman FL, Hidemura R, Peters RL. et al. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med 1966; 64: 341-351
350 Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore) 2014; 93: 135-142
351 Malagari K, Nikita A, Alexopoulou E. et al. Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients. Hepatogastroenterology 2005; 52: 558-562
352 Kiafar C, Gilani N. Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 2008; 7: 313-320
353 Singh A, Bajwa A, Shujaat A. Evidence-based review of the management of hepatic hydrothorax. Respiration 2013; 86: 155-173
354 Huang PM, Chang YL, Yang CY. et al. The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding. J Thorac Cardiovasc Surg 2005; 130: 141-145
355 Rubinstein D, McInnes IE, Dudley FJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology 1985; 88: 188-191
356 Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002; 346: 1971-1977
357 Xiol X, Castellote J, Cortes-Beut R. et al. Usefulness and complications of thoracentesis in cirrhotic patients. Am J Med 2001; 111: 67-69
358 Gordon CE, Feller-Kopman D, Balk EM. et al. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med 2010; 170: 332-339
359 Schildhouse R, Lai A, Barsuk JH. et al. Safe and Effective Bedside Thoracentesis: A Review of the Evidence for Practicing Clinicians. J Hosp Med 2017; 12: 266-276
360 Gurung P, Goldblatt M, Huggins JT. et al. Pleural fluid analysis and radiographic, sonographic, and echocardiographic characteristics of hepatic hydrothorax. Chest 2011; 140: 448-453
361 Bielsa S, Porcel JM, Castellote J. et al. Solving the Light’s criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012; 17: 721-726
362 Tu CY, Chen CH. Spontaneous bacterial empyema. Curr Opin Pulm Med 2012; 18: 355-358
363 Bhattacharya A, Mittal BR, Biswas T. et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol 2001; 16: 317-321
364 Ajmi S, Hassine H, Guezguez M. et al. Isotopic exploration of hepatic hydrothorax: ten cases. Gastroenterol Clin Biol 2004; 28: 462-466
365 Huang PM, Han YY, Kuo SW. et al. Color Doppler ultrasonography in detecting transdiaphragmatic flow of hepatic hydrothorax: correlation with thoracoscopic findings. J Thorac Cardiovasc Surg 2009; 138: 1251-1252
366 Tamano M, Hashimoto T, Kojima K. et al. Diagnosis of hepatic hydrothorax using contrast- enhanced ultrasonography with intraperitoneal injection of Sonazoid. J Gastroenterol Hepatol 2010; 25: 383-386
367 Kaplan LM, Epstein SK, Schwartz SL. et al. Clinical, echocardiographic, and hemodynamic evidence of cardiac tamponade caused by large pleural effusions. Am J Respir Crit Care Med 1995; 151: 904-908
368 Atiemo K, Skaro A, Maddur H. et al. Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (</=15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data. Am J Transplant 2017; 17: 2410-2419
369 Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients with tense cirrhotic ascites. Hepatology 1994; 20: 825-828
370 Castellote J, Xiol X, Cortes-Beut R. et al. Complications of thoracentesis in cirrhotic patients with pleural effusion. Rev Esp Enferm Dig 2001; 93: 566-575
371 Feller-Kopman D, Berkowitz D, Boiselle P. et al. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84: 1656-1661
372 Liu LU, Haddadin HA, Bodian CA. et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004; 126: 142-148
373 Orman ES, Lok AS. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3: 582-586
374 Haas KP, Chen AC. Indwelling tunneled pleural catheters for the management of hepatic hydrothorax. Curr Opin Pulm Med 2017; 23: 351-356
375 Chen A, Massoni J, Jung D. et al. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study. Ann Am Thorac Soc 2016; 13: 862-866
376 Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007; 41 (Suppl. 03) S344-S5351
377 Gordon FD, Anastopoulos HT, Crenshaw W. et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25: 1366-1369
378 Jeffries MA, Kazanjian S, Wilson M. et al. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg 1998; 4: 416-423
379 Siegerstetter V, Deibert P, Ochs A. et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13: 529-534
380 Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002; 13: 385-390
381 Wilputte JY, Goffette P, Zech F. et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 2007; 70: 6-10
382 Dhanasekaran R, West JK, Gonzales PC. et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol 2010; 105: 635-641
383 Ditah IC, Al Bawardy BF, Saberi B. et al. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta- analysis. World J Hepatol 2015; 7: 1797-1806
384 Falchuk KR, Jacoby I, Colucci WS. et al. Tetracycline-induced pleural symphysis for recurrent hydrothorax complicating cirrhosis. A new approach to treatment. Gastroenterology 1977; 72: 319-321
385 Milanez de Campos JR, Filho LO, de Campos Werebe E. et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000; 118: 13-17
386 Ferrante D, Arguedas MR, Cerfolio RJ. et al. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol 2002; 97: 3172-3175
387 Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg 2006; 82: 457-459
388 Huang PM, Kuo SW, Lee JM. Thoracoscopic diaphragmatic repair for refractory hepatic hydrothorax: application of pleural flap and mesh onlay reinforcement. Thorac Cardiovasc Surg 2006; 54: 47-50
389 Jung Y. Surgical Treatment of Hepatic Hydrothorax: A “Four-Step Approach”. Ann Thorac Surg 2016; 101: 1195-1197
390 Huang PM, Kuo SW, Chen JS. et al. Thoracoscopic Mesh Repair of Diaphragmatic Defects in Hepatic Hydrothorax: A 10-Year Experience. Ann Thorac Surg 2016; 101: 1921-1927
391 Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014; 20: 352-357
392 Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016; 61: 3321-3334
393 Xiol X, Tremosa G, Castellote J. et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005; 18: 672-675
394 Serste T, Moreno C, Francoz C. et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol 2010; 22: 207-212
395 Endo K, Iida T, Yagi S. et al. Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation. Surg Today 2014; 44: 2293-2299
396 Sese E, Xiol X, Castellote J. et al. Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema. J Clin Gastroenterol 2003; 36: 75-77
397 Ackerman Z, Reynolds TB. Evaluation of pleural fluid in patients with cirrhosis. J Clin Gastroenterol 1997; 25: 619-622
398 Xiol X, Castellvi JM, Guardiola J. et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996; 23: 719-723
399 Chen TA, Lo GH, Lai KH. Risk factors for spontaneous bacterial empyema in cirrhotic patients with hydrothorax. J Chin Med Assoc 2003; 66: 579-586
400 Castellote J, Lopez C, Gornals J. et al. Use of reagent strips for the rapid diagnosis of spontaneous bacterial empyema. J Clin Gastroenterol 2005; 39: 278-281
401 Chen CH, Shih CM, Chou JW. et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver International 2011; 31: 417-424
402 Ewig S, Hoffken G, Kern WV. et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016. Pneumologie 2016; 70: 151-200
403 Rodriguez-Roisin R, Krowka MJ, Herve P. et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880
404 Fuhrmann V, Madl C, Mueller C. et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131: 69-75
405 Kaymakoglu S, Kahraman T, Kudat H. et al. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci 2003; 48: 556-560
406 Abrams GA, Jaffe CC, Hoffer PB. et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109: 1283-1288
407 DuBrock HM, Krowka MJ, Forde KA. et al. Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant. Chest 2018; 153: 414-426
408 Fallon MB, Krowka MJ, Brown RS. et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135: 1168-1175
409 Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014; 59: 1627-1637
410 Palma DT, Philips GM, Arguedas MR. et al. Oxygen desaturation during sleep in hepatopulmonary syndrome. Hepatology 2008; 47: 1257-1263
411 Pascasio JM, Grilo I, Lopez-Pardo FJ. et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant 2014; 14: 1391-1399
412 Grilo-Bensusan I, Pascasio-Acevedo JM. Hepatopulmonary syndrome: What we know and what we would like to know. World J Gastroenterol 2016; 22: 5728-57241
413 Arguedas MR, Singh H, Faulk DK. et al. Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol 2007; 5: 749-754
414 Krowka MJ, Fallon MB, Kawut SM. et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 2016; 100: 1440-1452
415 Bundesärztekammer. Richtlinien zur Organtransplantation gem. § 16 TPG. Deutsches Ärzteblatt 2017; 114: A1-A20
416 Grilo I, Pascasio JM, Lopez-Pardo FJ. et al. Hepatopulmonary syndrome: which blood gas analysis criteria and position should we use for diagnosis?. Rev Esp Enferm Dig 2017; 109: 843-849
417 Tonelli AR, Naal T, Dakkak W. et al. Assessing the kinetics of microbubble appearance in cirrhotic patients using transthoracic saline contrast-enhanced echocardiography. Echocardiography 2017; 34: 1439-1446
418 Vedrinne JM, Duperret S, Bizollon T. et al. Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest 1997; 111: 1236-1240
419 Abrams GA, Nanda NC, Dubovsky EV. et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114: 305-310
420 Krowka MJ, Wiseman GA, Burnett OL. et al. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. Chest 2000; 118: 615-624
421 de Queiros AS, Brandao SC, Macedo LG. et al. Evaluation of normality and reproducibility parameters of scintigraphy with (99m)Tc-MAA in the diagnosis of intrapulmonary vascular dilatations. Ann Nucl Med 2015; 29: 46-51
422 Grilo I, Pascasio JM, Tirado JL. et al. The utility of the macro-aggregated albumin lung perfusion scan in the diagnosis and prognosis of hepatopulmonary syndrome in cirrhotic patients candidates for liver transplantation. Rev Esp Enferm Dig 2017; 109: 335-343
423 Koksal D, Kacar S, Koksal AS. et al. Evaluation of intrapulmonary vascular dilatations with high- resolution computed thorax tomography in patients with hepatopulmonary syndrome. J Clin Gastroenterol 2006; 40: 77-83
424 Surani SR, Mendez Y, Anjum H. et al. Pulmonary complications of hepatic diseases. World J Gastroenterol 2016; 22: 6008-6015
425 Cosarderelioglu C, Cosar AM, Gurakar M. et al. Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature. J Clin Transl Hepatol 2016; 4: 47-53
426 Schenk P, Schoniger-Hekele M, Fuhrmann V. et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125: 1042-1052
427 Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-1129
428 Boyer TD, Haskal ZJ. American Association for the Study of Liver D. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51: 306
429 Grady K, Gowda S, Kingah P. et al. Coil embolization of pulmonary arteries as a palliative treatment of diffuse type I hepatopulmonary syndrome. Respir Care 2015; 60: e20-e25
430 Krowka MJ, Mandell MS, Ramsay MA. et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-182
431 Iyer VN, Swanson KL, Cartin-Ceba R. et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology 2013; 57: 2427-2435
432 Ferenci P, Lockwood A, Mullen K. et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721
433 Conn HO, Lieberthal MM. The Syndrome of portal-systemic encephalopathy. In: Conn HO, Lieberthal MM. eds. The hepatic coma syndromes and lactulose. Williams & Wilkins; 1979: 1-45
434 Häussinger DCJ, Kircheis G. et al. Definition and assessment of low-grade hepatic encephalopathy. In: Häussinger DKG, Schliess F. eds. Hepatic Encephalopathy and Nitrogen Metabolism. Dordrecht: Springer; 2006: 423-432
435 Häussinger D, Blei A. Hepatic encephalopathy. In: Rodes JBJP, Blei AT, Reichen J. et al. eds. Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd. Edition Oxford: Wiley-Blackwell; 2007: 728-760
436 Vilstrup H, Amodio P, Bajaj J. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60: 715-735
437 Haussinger D, Sies H. Hepatic encephalopathy: clinical aspects and pathogenetic concept. Arch Biochem Biophys 2013; 536: 97-100
438 Gorg B, Schliess F, Haussinger D. Osmotic and oxidative/nitrosative stress in ammonia toxicity and hepatic encephalopathy. Arch Biochem Biophys 2013; 536: 158-163
439 Gorg B, Qvartskhava N, Bidmon HJ. et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology 2010; 52: 256-265
440 Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-1165
441 Haussinger D, Schliess F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. Neurochem Int 2005; 47: 64-70
442 Venturini I, Corsi L, Avallone R. et al. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. Scand J Gastroenterol 2001; 36: 423-425
443 Haussinger D, Steeb R, Kaiser S. et al. Nitrogen metabolism in normal and cirrhotic liver. Adv Exp Med Biol 1990; 272: 47-64
444 Haussinger D, Kircheis G, Fischer R. et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000; 32: 1035-1038
445 Timmermann L, Gross J, Butz M. et al. Mini-asterixis in hepatic encephalopathy induced by pathologic thalamo-motor-cortical coupling. Neurology 2003; 61: 689-692
446 Timmermann L, Butz M, Gross J. et al. Impaired cerebral oscillatory processing in hepatic encephalopathy. Clin Neurophysiol 2008; 119: 265-272
447 Butz M, Timmermann L, Braun M. et al. Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy. Acta Neurol Scand 2010; 122: 27-35
448 Kahlbrock N, Butz M, May ES. et al. Lowered frequency and impaired modulation of gamma band oscillations in a bimodal attention task are associated with reduced critical flicker frequency. Neuroimage 2012; 61: 216-227
449 Saunders JB, Walters JR, Davies AP. et al. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed) 1981; 282: 263-266
450 Romero-Gomez M, Boza F, Garcia-Valdecasas MS. et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-2723
451 Jepsen P, Ott P, Andersen PK. et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: 1675-1682
452 Labenz C, Worns MA, Schattenberg JM. et al. Epidemiology of hepatic encephalopathy in german hospitals – the EpHE study. Z Gastroenterol 2017; 55: 741-747
453 Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (Suppl. 01) 3-9
454 Srivastava A, Mehta R, Rothke SP. et al. Fitness to drive in patients with cirrhosis and portal- systemic shunting: a pilot study evaluating driving performance. Journal of Hepatology 1994; 21: 1023-1028
455 Wein C, Koch H, Popp B. et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-745
456 Bajaj JS, Hafeezullah M, Hoffmann RG. et al. Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008; 47: 596-604
457 Kircheis G, Knoche A, Hilger N. et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009; 137: 1706-1715 e1–9
458 Cordoba J, Cabrera J, Lataif L. et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998; 27: 339-345
459 Moscucci F, Nardelli S, Pentassuglio I. et al. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. Liver Int 2011; 31: 1505-1510
460 Hartmann IJ, Groeneweg M, Quero JC. et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95: 2029-2034
461 Bustamante J, Rimola A, Ventura PJ. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-895
462 Bajaj JS, Schubert CM, Heuman DM. et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138: 2332-2340
463 Riggio O, Ridola L, Pasquale C. et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011; 9: 181-183
464 Amodio P, Del Piccolo F, Pettenò E. et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. Journal of Hepatology 2001; 35: 37-45
465 Schomerus H, Hamster W, Blunck H. et al. Latent portasystemic encephalopathy. Digestive Diseases and Sciences 1981; 26: 622-630
466 Rikkers L, Jenko P, Rudman D. et al. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462-469
467 Tarter RE, Hegedus AM, Van Thiel DH. et al. Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 1984; 86: 1421-1427
468 Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986; 3: 75-82
469 Dhiman RK, Chawla YK. Minimal hepatic encephalopathy: time to recognise and treat. Trop Gastroenterol 2008; 29: 6-12
470 Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37-41
471 Wunsch E, Szymanik B, Post M. et al. Minimal hepatic encephalopathy does not impair health- related quality of life in patients with cirrhosis: a prospective study. Liver Int 2011; 31: 980-984
472 Marchesini G, Bianchi G, Amodio P. et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-178
473 Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health- related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-1626
474 Bao ZJ, Qiu DK, Ma X. et al. Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007; 13: 3003-3008
475 Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 3609-3615
476 Groeneweg M, Quero JC, De Bruijn I. et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-49
477 Labenz C, Baron JS, Toenges G. et al. Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Aliment Pharmacol Ther 2018; 48: 313-321
478 Gillmann A, Gerharz CD, Müssig K. Diagnostik und Therapie der hepatischen Enzephalopathie. Dtsch med Wochenschr 2012; 137: 29-33
479 Conn HO. Quantifying the severity of hepatic encephalopathy. In: Conn HO, Bircher J. eds. Hepatic encephalopathy: Syndromes and therapies. East Lansing, Michigan: Medi-Ed Press; 1994: 13-26
480 Kircheis G, Hilger N, Haussinger D. Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. Gastroenterology 2014; 146: 961-969
481 Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis 2004; 19: 281-312
482 Quero JC, Schalm SW. Subclinical Hepatic Encephalopathy. Semin Liver Dis 1996; 16: 321-328
483 Elsass P, Lund Y, Ranek L. Encephalopathy in patients with cirrhosis of the liver. A neuropsychological study. Scand J Gastroenterol 1978; 13: 241-247
484 Gilberstadt SJ, Gilberstadt H, Zieve L. et al. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980; 140: 519-521
485 Tarter RE, Carra J, Switala J. et al. Sequential concept formation capacity in subclinical (latent) portal-systemic encephalopathy. Int J Neurosci 1987; 32: 891-894
486 Gundling F, Seidl H, Schmidt T. et al. Blood ammonia level in liver cirrhosis: a conditio sine qua non to confirm hepatic encephalopathy?. Eur J Gastroenterol Hepatol 2008; 20: 246-247
487 Bajaj JS, Etemadian A, Hafeezullah M. et al. Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. Hepatology 2007; 45: 833-834
488 Bajaj JS, Saeian K, Verber MD. et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007; 102: 754-760
489 Bajaj JS, Hafeezullah M, Franco J. et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1591-1600 e1
490 Amodio P, Ridola L, Schiff S. et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2010; 139: 510-518, 518 e1–2
491 Allampati S, Duarte-Rojo A, Thacker LR. et al. 589 Two Testing Strategies for Covert Hepatic Encephalopathy Diagnosis Stabilizes Agreement Between Sites in a Multi-Center Analysis: Validation of the EASL/AASLD He Guidelines. Gastroenterology 2015; 148: S-988
492 Weissenborn K, Ennen JC, Schomerus H. et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-773
493 Weissenborn K, Ruckert N, Hecker H. et al. The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol 1998; 28: 646-653
494 Schomerus H, Hamster W. Neuropsychological aspects of portal-systemic encephalopathy. Metab Brain Dis 1998; 13: 361-377
495 Weissenborn K, Scholz M, Hinrichs H. et al. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 1990; 75: 289-295
496 Guerit JM, Amantini A, Fischer C. et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 789-796
497 Randolph C, Hilsabeck R, Kato A. et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629-635
498 Kircheis G, Wettstein M, Timmermann L. et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-366
499 Kircheis G, Bode JG, Hilger N. et al. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. Eur J Gastroenterol Hepatol 2009; 21: 1383-1394
500 Romero-Gomez M, Cordoba J, Jover R. et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-885
501 Sharma P, Sharma BC, Puri V. et al. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47: 67-73
502 Biecker E, Hausdorfer I, Grunhage F. et al. Critical flicker frequency as a marker of hepatic encephalopathy in patients before and after transjugular intrahepatic portosystemic shunt. Digestion 2011; 83: 24-31
503 Berlioux P, Robic MA, Poirson H. et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology 2014; 59: 622-629
504 Ampuero J, Simon M, Montoliu C. et al. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. Gastroenterology 2015; 149: 1483-1489
505 Sharma P, Kumar A, Singh S. et al. Inhibitory control test, critical flicker frequency, and psychometric tests in the diagnosis of minimal hepatic encephalopathy in cirrhosis. Saudi J Gastroenterol 2013; 19: 40-44
506 Parsons-Smith BG, Summerskill WH, Dawson AM. et al. The electroencephalograph in liver disease. Lancet 1957; 273: 867-871
507 Schiff S, Casa M, Di Caro V. et al. A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology 2016; 63: 1651-1659
508 Amodio P, Quero JC, Del Piccolo F. et al. Diagnostic tools for the detection of subclinical hepatic encephalopathy: comparison of standard and computerized psychometric tests with spectral- EEG. Metab Brain Dis 1996; 11: 315-327
509 Amodio P, Marchetti P, Del Piccolo F. et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999; 110: 1334-1344
510 Kullmann F, Hollerbach S, Lock G. et al. Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease. Eur J Gastroenterol Hepatol 2001; 13: 513-522
511 Yang SS, Chu NS, Liaw YF. Somatosensory evoked potentials in hepatic encephalopathy. Gastroenterology 1985; 89: 625-630
512 Yang SS, Chu NS, Liaw YF. Brainstem auditory evoked potentials in hepatic encephalopathy. Hepatology 1986; 6: 1352-1355
513 Johansson U, Andersson T, Persson A. et al. Visual evoked potential – a tool in the diagnosis of hepatic encephalopathy?. J Hepatol 1989; 9: 227-233
514 Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology 1935; 18: 643-662
515 Jensen AR, Rohwer Jr WD. The Stroop color-word test: a review. Acta Psychol (Amst) 1966; 25: 36-93
516 MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991; 109: 163-203
517 Amodio P, Cordoba J. Smart applications for assessing minimal hepatic encephalopathy: novelty from the app revolution. Hepatology 2013; 58: 844-846
518 Bajaj JS, Heuman DM, Sterling RK. et al. Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. Clin Gastroenterol Hepatol 2015; 13: 1828-1835 e1
519 Allampati S, Duarte-Rojo A, Thacker LR. et al. Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. Am J Gastroenterol 2016; 111: 78-86
520 Bajaj JS, Frederick RT, Bass NM. et al. Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary. Metab Brain Dis 2016; 31: 1081-1093
521 Campagna F, Montagnese S, Ridola L. et al. The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology 2017; 66: 198-208
522 Nabi E, Thacker LR, Wade JB. et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol 2014; 12: 1384-1389 e2
523 Montagnese S, Balistreri E, Schiff S. et al. Covert hepatic encephalopathy: agreement and predictive validity of different indices. World J Gastroenterol 2014; 20: 15756-157562
524 Iduru S, Mullen KD. The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1455-1456
525 Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM 2006; 8: 433-435
526 Dhiman RK, Saraswat VA, Sharma BK. et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 2010; 25: 1029-1041
527 Gundling F, Zelihic E, Seidl H. et al. How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol 2013; 12: 108-114
528 Ong JP, Aggarwal A, Krieger D. et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-193
529 Kramer L, Tribl B, Gendo A. et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000; 31: 30-34
530 Nicolao F, Efrati C, Masini A. et al. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 2003; 38: 441-446
531 Shah NJ, Neeb H, Kircheis G. et al. Quantitative cerebral water content mapping in hepatic encephalopathy. Neuroimage 2008; 41: 706-717
532 Kale RA, Gupta RK, Saraswat VA. et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006; 43: 698-706
533 Krieger S, Jauss M, Jansen O. et al. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996; 111: 147-155
534 Spahr L, Burkhard PR, Grotzsch H. et al. Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2002; 17: 399-413
535 Zafiris O, Kircheis G, Rood HA. et al. Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. NeuroImage 2004; 22: 541-552
536 Miese F, Kircheis G, Wittsack HJ. et al. 1H-MR Spectroscopy, Magnetization Transfer, and Diffusion-Weighted Imaging in Alcoholic and Nonalcoholic Patients with Cirrhosis with Hepatic Encephalopathy. American Journal of Neuroradiology 2006; 27: 1019
537 Jitkritsadakul O, Bhidayasiri R. Physicians’ role in the determination of fitness to drive in patients with Parkinson’s disease: systematic review of the assessment tools and a call for national guidelines. J Clin Mov Disord 2016; 3: 14
538 Riggio O, Nardelli S, Gioia S. et al. Management of hepatic encephalopathy as an inpatient. Clinical Liver Disease 2015; 5: 79-82
539 Ruiz-Margain A, Macias-Rodriguez RU, Ampuero J. et al. Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. World J Gastroenterol 2016; 22: 10064-10070
540 Pantham G, Post A, Venkat D. et al. A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis. Dig Dis Sci 2017; 62: 2166-2173
541 Riggio O, Ridola L, Pasquale C. Hepatic encephalopathy therapy: An overview. World J Gastrointest Pharmacol Ther 2010; 1: 54-63
542 Guevara M, Baccaro ME, Torre A. et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104: 1382-1389
543 Strauss E, Gomes de Sa Ribeiro Mde F. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann Hepatol 2003; 2: 41-45
544 Strauss E, da Costa MF. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 1998; 45: 900-904
545 Rolando N, Wade J, Davalos M. et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-739
546 Merli M, Lucidi C, Pentassuglio I. et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol 2013; 59: 243-250
547 Hung TH, Lay CJ, Chang CM. et al. The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect 2013; 141: 2671-2678
548 Dieuvil M, Malaty J. Uncommon cause of acute encephalopathy in liver cirrhosis. BMJ Case Rep 2016 2016.
549 del Olmo JA, Pena A, Serra MA. et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000; 32: 19-24
550 Wen J, Liu Q, Song J. et al. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Digestion 2013; 87: 132-138
551 Sharma P, Agrawal A, Sharma BC. et al. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2011; 26: 996-1003
552 Micklefield GH, Schwegler U, Huppe D. et al. Orthograde intestinal irrigation with a mannitol solution in reducing hepatic encephalopathy in patients with liver cirrhosis and gastrointestinal hemorrhage. Z Gastroenterol 1989; 27: 374-377
553 Tromm A, Griga T, Greving I. et al. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000; 47: 473-477
554 Rahimi RS, Singal AG, Cuthbert JA. et al. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 2014; 174: 1727-1733
555 Guevara M, Baccaro ME, Rios J. et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010; 30: 1137-1142
556 Hung TH, Tsai CC, Tseng KC. et al. High Mortality of Cirrhotic Patients With End-Stage Renal Disease. Medicine (Baltimore) 2016; 95: e3057
557 Hung TH, Tseng CW, Tseng KC. et al. Effect of renal function impairment on the mortality of cirrhotic patients with hepatic encephalopathy: a population-based 3-year follow-up study. Medicine (Baltimore) 2014; 93: e79
558 Sponholz C, Matthes K, Rupp D. et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure – a prospective, randomised crossover study. Crit Care 2016; 20: 2
559 Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol 2016; 160: 94-97
560 Goh ET, Andersen ML, Morgan MY. et al. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017; 8: CD002798
561 Grimm G, Ferenci P, Katzenschlager R. et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; 2: 1392-1394
562 Groeneweg M, Gyr K, Amrein R. et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo- controlled multicentre trial. Electroencephalogr Clin Neurophysiol 1996; 98: 29-34
563 Gyr K, Meier R, Haussler J. et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996; 39: 319-324
564 Khan MA, Cholankeril G, Howden CW. Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding?. Gastroenterology 2017; 152: 2076
565 Tsai CF, Chen MH, Wang YP. et al. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology 2017; 152: 134-141
566 Bian J, Wang A, Lin J. et al. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017; 96: e6723
567 Quirino M, Rossi S, Schinzari G. et al. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy. Medicine (Baltimore) 2017; 96: e6522
568 Jain S, Jain S, Kapoor G. Imatinib-associated massive upper gastrointestinal hemorrhage and hepatic encephalopathy in a child with Philadelphia positive acute lymphoblastic leukemia: A case report and review of the literature. South Asian J Cancer 2014; 3: 234-235
569 Seymour CA, Whelan K. Dietary management of hepatic encephalopathy. BMJ 1999; 318: 1364-1365
570 Campollo O, Sprengers D, Dam G. et al. Protein tolerance to standard and high protein meals in patients with liver cirrhosis. World J Hepatol 2017; 9: 667-676
571 Jepsen P, Christensen J, Weissenborn K. et al. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study. BMC Gastroenterol 2016; 16: 77
572 Montano-Loza AJ, Duarte-Rojo A, Rose CF. Sarcopenia and Myosteatosis Increase the Risk of Hepatic Encephalopathy in Cirrhotic Patients (in Poster Session 1: Encephalopathy and Other Complications). Hepatology; Special Issue: The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014. 2014 60. 384A-385A
573 Montano-Loza AJ, Duarte-Rojo A, Bhanji RA. et al. Cirrhotic patients with sarcopenia and sarcopenic-obesity have an increased risk of hyperammonemia and hepatic encephalopathy. Am J Gastroenterol 2015; 110 (Suppl. 01) S875-S5877
574 Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-1010
575 Iwasa M, Sugimoto R, Mifuji-Moroka R. et al. Factors contributing to the development of overt encephalopathy in liver cirrhosis patients. Metab Brain Dis 2016; 31: 1151-1156
576 Merola J, Chaudhary N, Qian M. et al. Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Clin Med 2014; 3: 359-372
577 Jimenez JV, Carrillo-Perez DL, Rosado-Canto R. et al. Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci 2017; 62: 1855-1871
578 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015; 13: 2048-2061
579 European Association for the Study of the Liver. Electronic address eee, Clinical practice guidelines p, Wendon J et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047-1081
580 Maheshwari R, Subramanian RM. On the Brink of Death: Managing Acute Liver Failure. Am J Gastroenterol 2017; 112: 200-206
581 Lautz HU, Selberg O, Korber J. et al. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 70: 478-486
582 Owen OE, Trapp VE, Reichard Jr GA. et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest 1983; 72: 1821-1832
583 Plauth M, Cabre E, Riggio O. et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285-294
584 Nguyen DL, Morgan T. Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view. Hepatol Int 2014; 8: 447-451
585 Olde Damink SW, Jalan R, Redhead DN. et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-1171
586 Merli M, Giusto M, Lucidi C. et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis 2013; 28: 281-284
587 Hanai T, Shiraki M, Watanabe S. et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Res 2017; 47: 1359-1367
588 Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3: 225-237
589 Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 16: CD008344
590 Ney M, Vandermeer B, van Zanten SJ. et al. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther 2013; 37: 672-679
591 Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol 2012; 27: 430-441
592 Gluud LL, Dam G, Les I. et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017; 5: CD001939
593 Zenith L, Meena N, Ramadi A. et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1920-1926 e2
594 Kumar A, Davuluri G, Silva RNE. et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology 2017; 65: 2045-2058
595 Bianchi GP, Marchesini G, Fabbri A. et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993; 233: 385-392
596 Gheorghe L, Iacob R, Vadan R. et al. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. Rom J Gastroenterol 2005; 14: 231-238
597 Maharshi S, Sharma BC, Sachdeva S. et al. Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol 2016; 14: 454-460 e3 ; quiz e33
598 Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy. Metab Brain Dis 2016; 31: 1289-1294
599 Grungreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol 2016; 15: 7-16
600 Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T. et al. A systematic review and meta- analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013; 12: 74
601 Peres WA, Chaves GV, Goncalves JC. et al. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease. Br J Nutr 2011; 106: 1724-1731
602 Bemeur C, Butterworth RF. Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications. J Clin Exp Hepatol 2015; 5: S131-S140
603 AASLD, EASL. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014; 61: 642-659
604 Goldbecker A, Weissenborn K, Hamidi Shahrezaei G. et al. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut 2013; 62: 1497-1504
605 Mette ML, Hendrik V. Diagnosing covert hepatic encephalopathy. Clinical Liver Disease 2015; 5: 71-74
606 Soriano G, Bajaj JS. Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue!. Hepatology 2017; 66: 10-12
607 Bajaj JS, Cordoba J, Mullen KD. et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-747
608 Bajaj JS, Kassam Z, Fagan A. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017; 66: 1727-1738
609 Wijdicks EF. Hepatic Encephalopathy. N Engl J Med 2016; 375: 1660-1670
610 Bai M, He C, Yin Z. et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther 2014; 40: 63-71
611 Stauch S, Kircheis G, Adler G. et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 856-864
612 Kircheis G, Nilius R, Held C. et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double- blind study. Hepatology 1997; 25: 1351-1360
613 Romero-Gomez M, Jover M, Del Campo JA. et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010; 153: 281-288
614 Morgan MY. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Metab Brain Dis 2016; 31: 1361-1364
615 Bothe MK, Maathuis AJH, Bellmann S. et al. Dose-Dependent Prebiotic Effect of Lactulose in a Computer-Controlled In Vitro Model of the Human Large Intestine. Nutrients 2017; 9: 767
616 Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology 2016; 64: 908-922
617 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 2016; 4: CD003044
618 Luo M, Li L, Lu CZ. et al. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011; 23: 1250-1257
619 Jiang Q, Jiang XH, Zheng MH. et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20: 1064-1070
620 Eltawil KM, Laryea M, Peltekian K. et al. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-777
621 Wu D, Wu SM, Lu J. et al. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract 2013; 2013: 236963
622 22. ROTE LISTE 2016. Frankfurt/Main: Rote Liste Service GmbH (Verlag); 2016
623 Lachar J, Bajaj JS. Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis. Semin Liver Dis 2016; 36: 327-330
624 Sharma BC, Singh J. Probiotics in management of hepatic encephalopathy. Metab Brain Dis 2016; 31: 1295-1301
625 Xu J, Ma R, Chen LF. et al. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int 2014; 13: 354-60
626 Dalal R, McGee RG, Riordan SM. et al. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017; 2: CD008716
627 Viramontes Horner D, Avery A, Stow R. The Effects of Probiotics and Symbiotics on Risk Factors for Hepatic Encephalopathy: A Systematic Review. J Clin Gastroenterol 2017; 51: 312-323
628 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016; 43 (Suppl. 01) 11-26
629 Kimer N, Pedersen JS, Tavenier J. et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol 2018; 33: 307-314
630 Kimer N, Pedersen JS, Busk TM. et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017; 65: 592-603
631 Kimer N, Krag A, Moller S. et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014; 40: 123-132
632 Sharma BC, Sharma P, Lunia MK. et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-1463
633 Festi D, Vestito A, Mazzella G. et al. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006; 73 (Suppl. 01) 94-101
634 Zullo A, Hassan C, Ridola L. et al. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3: 62-67
635 Cacciottolo TM, Kingdon A, Alexander GJ. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins. Clin Gastroenterol Hepatol 2014; 12: 1765
636 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081
637 Manning RT, Delp M. Management of hepatocerebral intoxication. N Engl J Med 1958; 258: 55-62
638 Rolachon A, Zarski JP, Lutz JM. et al. Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study. Gastroenterol Clin Biol 1994; 18: 1057-1062
639 Naderian M, Akbari H, Saeedi M. et al. Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East J Dig Dis 2017; 9: 12-19
640 Kersh ES, Rifkin H. Lactulose enemas. Ann Intern Med 1973; 78: 81-84
641 Ratnaike RN, Hicks EP, Hislop IG. The rectal administration of lactulose. Aust N Z J Med 1975; 5: 137-140
642 Van Waes L, van Egmond J, Demeulenaere L. Emergency treatment of portal-systemic encephalopathy with lactulose enemas. A controlled study. Acta Clin Belg 1979; 34: 122-129
643 Jover-Cobos M, Khetan V, Jalan R. Treatment of hyperammonemia in liver failure. Curr Opin Clin Nutr Metab Care 2014; 17: 105-110
644 Rahimi RS, Rockey DC. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia. Semin Liver Dis 2016; 36: 48-55
645 Sidhu SS, Sharma BC, Goyal O. et al. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology 2017; 67: 700-710
646 Bai M, Yang Z, Qi X. et al. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28: 783-792
647 Goh ET, Stokes CS, Vilstrup H. et al. l-Ornithine l-Aspartate for Hepatic Encephalopathy: A Systematic Review with Meta-Analyses of Randomised Controlled Trials. Journal of Clinical and Experimental Hepatology 2017; 7: S65-S66
648 Alvares-da-Silva MR, de Araujo A, Vicenzi JR. et al. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 956-963
649 Poo JL, Gongora J, Sanchez-Avila F. et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose- controlled study. Ann Hepatol 2006; 5: 281-288
650 Jiang Q, Jiang XH, Zheng MH. et al. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14
651 Acharya SK, Bhatia V, Sreenivas V. et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136: 2159-2168
652 Rockey DC, Vierling JM, Mantry P. et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59: 1073-1083
653 McGuire BM, Zupanets IA, Lowe ME. et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51: 2077-2085
654 Ventura-Cots M, Concepcion M, Arranz JA. et al. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016; 9: 823-835
655 Ventura-Cots M, Arranz JA, Simon-Talero M. et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 2013; 47: 881-887
656 Kawaguchi T, Izumi N, Charlton MR. et al. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54: 1063-1070
657 Kawaguchi T, Taniguchi E, Sata M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract 2013; 28: 580-588
658 Park JG, Tak WY, Park SY. et al. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study. Medicine (Baltimore) 2017; 96: e6580
659 Marchesini G, Bianchi G, Merli M. et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801
660 Tsien C, Davuluri G, Singh D. et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology 2015; 61: 2018-2029
661 Courson A, Jones GM, Twilla JD. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes. J Pharm Pract 2016; 29: 212-217
662 Butt NI, Butt UI, Kakar A. et al. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?. J Coll Physicians Surg Pak 2018; 28: 115-117
663 Ahire K, Sonawale A. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. J Assoc Physicians India 2017; 65: 42-46
664 Sharma BC, Singh J, Srivastava S. et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol 2017; 32: 1234-1239
665 Abid S, Jafri W, Mumtaz K. et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak 2011; 21: 666-671
666 Sharma BC, Sharma P, Agrawal A. et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-891, 891 e1
667 Agrawal A, Sharma BC, Sharma P. et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107: 1043-1050
668 Tapper EB, Finkelstein D, Mittleman MA. et al. A Quality Improvement Initiative Reduces 30- Day Rate of Readmission for Patients With Cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 753-759
669 Sharma Barjesh C, Maharshi S. Prevention of hepatic encephalopathy recurrence. Clinical Liver Disease 2015; 5: 64-67
670 Les I, Doval E, Garcia-Martinez R. et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011; 106: 1081-1088
671 Dhiman RK, Rana B, Agrawal S. et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; 147: 1327-1337 e3
672 Ali B, Zaidi YA, Alam A. et al. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak 2014; 24: 269-273
673 Riggio O, Masini A, Efrati C. et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674-679
674 Leise MD, Kim WR. Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?. Gastroenterology 2010; 139: 1416-1418
675 Khokhar N, Qureshi MO, Ahmad S. et al. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease. J Gastroenterol Hepatol 2015; 30: 1420-1422
676 Neff GW, Jones M, Broda T. et al. Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 2012; 46: 168-171
677 Varakanahalli S, Sharma BC, Dahale AS. Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: A Double Blind Randomized Controlled Trial of L-Ornithine L-Aspartate vs. Placebo. Journal of Clinical and Experimental Hepatology 2017; 7: S60-S61
678 Varakanahalli S, Sharma BC, Srivastava S. et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol 2018; 30: 951-958
679 Mukund A, Rajesh S, Arora A. et al. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol 2012; 23: 1200-1206
680 Amodio P, Caregaro L, Pettenó E. et al. Vegetarian diets in hepatic encephalopathy: facts or fantasies?. Digestive and Liver Disease 2001; 33: 492-500
681 Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat?. Ann Hepatol 2017; 16: 115-122
682 Khanna R, Sarin SK. Non-cirrhotic portal hypertension – diagnosis and management. J Hepatol 2014; 60: 421-441
683 Sharma P, Sharma BC, Puri V. et al. Natural history of minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol 2009; 104: 885-890
684 Yadav SK, Goel A, Saraswat VA. et al. Evaluation of cognitivity, proinflammatory cytokines, and brain magnetic resonance imaging in minimal hepatic encephalopathy induced by cirrhosis and extrahepatic portal vein obstruction. J Gastroenterol Hepatol 2016; 31: 1986-1994
685 Faughnan ME, Palda VA, Garcia-Tsao G. et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87
686 Chavan A, Caselitz M, Gratz KF. et al. Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol 2004; 14: 2079-2085
687 El-Karaksy HM, Afifi O, Bakry A. et al. A pilot study using lactulose in management of minimal hepatic encephalopathy in children with extrahepatic portal vein obstruction. World J Pediatr 2017; 13: 70-75
688 Knirsch W, Benz DC, Buhr P. et al. Catheter interventional treatment of congenital portosystemic venous shunts in childhood. Catheter Cardiovasc Interv 2016; 87: 1281-1292
689 Brader RA, Kim KR. Transhepatic embolization of a congenital intrahepatic portosystemic shunt for the treatment of hepatic encephalopathy in a noncirrhotic patient using Amplatzer vascular plug device. Radiol Case Rep 2017; 12: 318-322
690 Matsuura T, Takahashi Y, Yanagi Y. et al. Surgical strategy according to the anatomical types of congenital portosystemic shunts in children. J Pediatr Surg 2016; 51: 2099-2104
691 Lam KC, Juttner HU, Reynolds TB. Spontaneous portosystemic shunt: relationship to spontaneous encephalopathy and gastrointestinal hemorrhage. Dig Dis Sci 1981; 26: 346-352
692 Riggio O, Efrati C, Catalano C. et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005; 42: 1158-1165
693 Qi X, Qi X, Zhang Y. et al. Prevalence and Clinical Characteristics of Spontaneous Splenorenal Shunt in Liver Cirrhosis: A Retrospective Observational Study Based on Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) Scans. Med Sci Monit 2017; 23: 2527-2534
694 Ohnishi K, Sato S, Saito M. et al. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol 1986; 81: 450-455
695 Gupta P, Sinha A, Sodhi KS. et al. Congenital Extrahepatic Portosystemic Shunts: Spectrum of Findings on Ultrasound, Computed Tomography, and Magnetic Resonance Imaging. Radiology Research and Practice 2015; 2015: 7
696 Laleman W, Simon-Talero M, Maleux G. et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57: 2448-2457
697 Moriya K, Kojima H, Matsumura M. et al. Disappearance of hepatic encephalopathy and improvement of liver function after surgical treatment of portal-systemic shunt in a patient with liver cirrhosis. Hepatogastroenterology 2003; 50: 1128-1132
698 Rossle M. TIPS: 25 years later. J Hepatol 2013; 59: 1081-1093
699 Somberg KA, Riegler JL, LaBerge JM. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90: 549-555
700 Riggio O, Ridola L, Angeloni S. et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol 2010; 53: 267-272
701 Casado M, Bosch J, Garcia-Pagan JC. et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-1303
702 Chung HH, Razavi MK, Sze DY. et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?. J Gastroenterol Hepatol 2008; 23: 95-101
703 Bai M, Qi X, Yang Z. et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol 2011; 26: 943-951
704 Suraweera D, Jimenez M, Viramontes M. et al. Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. J Clin Gastroenterol 2017; 51: 360-363
705 Nardelli S, Gioia S, Pasquale C. et al. Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol 2016; 111: 523-528
706 Fanelli F, Salvatori FM, Rabuffi P. et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon- expandable stent-graft. Am J Roentgenol 2009; 193: 1696-1702
707 LaBerge JM, Somberg KA, Lake JR. et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108: 1143-1151
708 Riggio O, Nardelli S, Moscucci F. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012; 16: 133-146
709 Pereira K, Carrion AF, Salsamendi J. et al. Endovascular Management of Refractory Hepatic Encephalopathy Complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm. Cardiovasc Intervent Radiol 2016; 39: 170-182
710 Pereira K, Carrion AF, Martin P. et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int 2015; 35: 2487-2494
711 Bajaj JS, Saeian K, Christensen KM. et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715
712 Mittal VV, Sharma BC, Sharma P. et al. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011; 23: 725-732
713 Saji S, Kumar S, Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol 2011; 32: 128-132
714 Shukla S, Shukla A, Mehboob S. et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011; 33: 662-671
715 Sharma K, Pant S, Misra S. et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol 2014; 20: 225-232
716 Sidhu SS, Goyal O, Mishra BP. et al. Rifaximin improves psychometric performance and health- related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-316
717 Bajaj JS, Heuman DM, Wade JB. et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487 e1
718 Nardone R, Taylor AC, Holler Y. et al. Minimal hepatic encephalopathy: A review. Neurosci Res 2016; 111: 1-12
719 Ferenci P. Diagnosis of minimal hepatic encephalopathy: still a challenge. Gut 2013; 62: 1394
720 Thuluvath PJ, Nuthalapati A, Price J. et al. Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments. J Clin Exp Hepatol 2016; 6: 3-9
721 Maharshi S, Sharma BC, Srivastava S. et al. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. Gut 2015; 64: 1341-1342